Abstract library

18 results for "Castro-Rivera".
#2301 Trends in Management of Gastro-Intestinal Neuroendocrine Tumors in Inflammatory Bowel Diseases: The Contribute of a Case Series.
Introduction: The risk to develop gastro-intestinal malignancies is higher in patients affected by inflammatory bowel diseases (IBD). Apart from colo-rectal cancer, related to a long standing inflammation, there is a growing evidence of neuroendocrine tumors (NETs) in these patients and a correlation between these two diseases has been postulated. We report four cases of NETs in IBD.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Doctor Stefano Rizza
#1252 Radio-chemotherapy versus Surgery in Non-metastatic Ano-rectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues Oncologues
Introduction: Neuroendocrine carcinomas (NEC) of the anus or the rectum are a rare disease, accounting for less than 1% of all digestive malignancies. Most are metastatic at diagnosis and treated with a platinum-based chemotherapy. No guidelines for localized tumors exist.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Bertrand Brieau
#1725 Safety of Lanreotide 120 mg ATG (LAN) in Combination with Metformin (MET) in Patients (pts) with Progressive Advanced Well-Differentiated (WD) Gastro-Intestinal (GI) or Lung Carcinoids. A Pilot, One-Arm, Open-Label, Prospective Study: The MetNET-2 Trial
Introduction: Anti proliferative effect of LAN ATG 120 mg has been investigated in 204 GI-NET pts in Clarinet study with a 53% reduction in risk of death/progression vs placebo. An increasing number of trials have associated MET with better outcome in cancer pts due to a reduction of insulin/IGF1 levels and modulation of AMPK and TSC1-2/mTOR. The retrospective PRIME-net study conducted on 445 Italian pts, suggest that addition of MET to everolimus and/or SSA provides clinical benefit in diabetic pancreatic NETs.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Sara Pusceddu
Authors: Prinzi N, Femia D, Concas L, Lo Russo G, ...
Keywords: lanreotide, metformin
#1888 Selective Transarterial Embolization of Gastro-Entero Pancreatic (GEP) Neuroendocrine Tumors (NET) with Advanced Locoregional Disease and/or Liver Metastases
Introduction: Selective transarterial embolization(TAE) and chemoembolization(TACE),are alternative options to systemic therapies in patients with GEP-NET G1/G2 with advanced locoregional disease and/or unresectable liver metastases
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dr Concepcion Blanco
Keywords: TACE, TAE, GEP-NET
#25 Predictors of response to radio-embolization (TheraSphere ®) treatment of neuro-endocrine liver metastasis
Introduction: Neuroendocrine tumors (NET) frequently metastasize to the liver. Most patients have diffuse, and therefore incurable, disease. NET liver metastasis has been shown to respond to yttrium-90 microspheres therapy. This study aims to define factors that predict response to radio-embolization in patients with NET liver metastases.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Mazen Hassanain
#788 A Novel Animal Model for Medullary Thyroid Carcinoma
Introduction: Medullary thyroid carcinoma (MTC) is a neuroendocrine cancer originating from calcitonin-producing C-cells. Surgical resection is the most effective treatment currently available. Understanding the molecular pathways mediating MTC is crucial for the development of novel therapies. Cyclin-dependent kinase 5 (Cdk5) and its activators, p35 and p25, have recently been implicated in MTC etiology. P25 is a cleavage product of p35 and the binding of p25 to Cdk5 leads to aberrant Cdk5 activity.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Karine Pozo
Authors: Pozo K, Castro-Rivera E, Tan C, Siegl V, ...
Keywords: thyroid, Cdk5
#2147 Nutritional Assessment and Vitamin Deficiencies in Patients with NETs
Introduction: As a result of disease or related to its management, patients with neuroendocrine tumours may have altered gut or pancreatic function that can cause nutritional deficiencies.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Mark Reynolds
Authors: Lim S, Reynolds M, Rees D A, Chaudhry R, ...
#358 Enhanced Combined 177Lu-DOTATATE and 90Y-DOTATATE Treatment of Patients with Metastatic Neuroendocrine Tumors Refractory to Conventional Therapy: An Ongoing Study.
Introduction: Neuroendocrine tumors (NETs) over-express somatostatin receptors (SRs) and the efficacy of peptide receptor radionuclide therapy (PRRT) with somatostatin analogues labeled with high activities of ß-emitting radioisotopes have been reported.
Conference:
Category: Basic
Presenting Author: Dr Andrew Mallia
#380 Diagnosis and Management of Insulinomas in a Tertiary Referral Center: A 10-Year Review
Introduction: Insulinomas are rare tumors. There are few reports of insulinoma from India. We present a retrospective analysis of patients with insulinoma evaluated at a tertiary referral center in South India.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Vijay Ramachandran
#972 Anti-Tumor Efficacy of Somatostatin Analogues (SSAs) in Patients with Neuroendocrine Tumors (NETs) According to Ki-67 Score: A Multicentric Study From ELIOS (Educational Learning Investigational Observational Study)
Introduction: SSAs have been demonstrated to have antiproliferative effects in ileal NETs. The 2010 WHO NET classification provides a grading score which can be helpful in predicting tumor response to SSA.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Antongiulio Faggiano
Keywords: NET, SSA, G1, G2, WHO classification
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.